Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. (Q37789224)

23 August 2017

Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. (English)

1 reference

23 August 2017

0 references

2

Shibo Jiang

1 reference

23 August 2017

Lifeng Cai

1

1 reference

23 August 2017

1 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

5

1 reference

23 August 2017

11

1 reference

23 August 2017

1813-1824

1 reference

Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins

23 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

New horizons: antiretroviral therapy in 1997.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Update on HAART in HIV.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

HIV-1 inhibition by a peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Core structure of gp41 from the HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Atomic structure of the ectodomain from HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Atomic structure of a thermostable subdomain of HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

An update in the development of HIV entry inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

HIV-1 gp41 fusion intermediate: a target for HIV therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Mechanisms of viral membrane fusion and its inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Selection of T1249-resistant human immunodeficiency virus type 1 variants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Sifuvirtide, a potent HIV fusion inhibitor peptide.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Potent D-peptide inhibitors of HIV-1 entry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

A metallopeptide assembly of the HIV-1 gp41 coiled coil is an ideal receptor in fluorescence detection of ligand binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Protein design of an HIV-1 entry inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

A template-assembled model of the N-peptide helix bundle from HIV-1 Gp-41 with high affinity for C-peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

NMR second site screening for structure determination of ligands bound in the hydrophobic pocket of HIV-1 gp41.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part I. fusion [corrected] inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Microbicides: stopping HIV at the gate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Poly(styrene-alt-maleic anhydride) derivatives as potent anti-HIV microbicide candidates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Orally active fusion inhibitor of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Identification of minimal sequence for HIV-1 fusion inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Structure-based design of substituted biphenyl ethylene ethers as ligands binding in the hydrophobic pocket of gp41 and blocking the helical bundle formation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000289

7 January 2021

Identifiers

DOI

10.1002/CMDC.201000289

1 reference

23 August 2017

1 reference

PubMed ID

20845360